#ASCO17 Twitter Highlights

I was not able to attend this year's ASCO Annual Meeting in Chicago so instead I followed the latest oncology news from the meeting via Twitter (#ASCO17).  I appreciate all the attendees who used the #gyncsm hashtag too.

Below find the tweets I found most interesting in the areas of gynecologic cancers, social media and survivorship.

Let's start first with how to read cancer related news:

6 things to keep in mind if you read cancer-related news in the next few days from #ASCO2017 https://t.co/8sOGGPZ0QS via @thejoyvictory

— Ash Paul (@pash22) June 2, 2017

Patient Reported Outcomes Leads to Improved survival

Online Tool for Reporting Symptoms Extends Survival: https://t.co/PQ42FruSRU #ASCO17

— ASCO (@ASCO) June 5, 2017

Impact of HPV vaccinations:

#ASCO17 News: Large study shows reduced oral #HPV infections with vaccine. https://t.co/EQppR0uWhH [Abstract 6003]

— Medscape (@Medscape) May 31, 2017

PD-1 Pathways in Gynecologic Cancers: 

#ASCO17 #ImmunoOnc Emens #bcsm #gyncsm - pic.twitter.com/yJmtN4qPAf

— Mike Thompson, MDPhD (@mtmdphd) June 1, 2017

Progress in High Grade Serous Ovarian Cancer:

#ASCO17 #gyncsm optimism in progress! pic.twitter.com/ndRFTDHIsm

— Elizabeth Dickson (@edicksonMD) June 2, 2017

Liquid Biopsy

Liquid Biopsies: The Current State of Research & Their Future in Clinical Practice https://t.co/RM89QvikIR #ASCO17 pic.twitter.com/V58sjxVf3d

— ASCO (@ASCO) June 2, 2017

Parp Inhibitors in Ovarian Cancer:

QOL on olaparib not different than placebo for patients with #ovariancancer. Delayed progression makes women feel better #gyncsm #ASCO17 pic.twitter.com/kycFXkEdq1

— Sarah Temkin (@temkins) June 2, 2017

Very nice diagram of PARP and ovarian cancer #gyncsm #gencsm #ASCO17 pic.twitter.com/gzWHAyZLup

— Erica Bednar (@EMBOSU) June 3, 2017

Resection of Recurrent OC:

Complete resection of recurrent #ovariancancer improves outcomes without increasing adverse events. #gyncsm. DESKTOP III. ASCO17 pic.twitter.com/AyCNpVzUqo

— Sarah Temkin (@temkins) June 2, 2017

ICON6:
"ICON6 is designed to evaluate the safety and efficacy of platinum-based chemotherapy in combination with cediranib in women with platinum-sensitive relapsed ovarian cancer . Cediranib is an oral targeted small molecule inhibitor of a key signalling molecule Vascular Endothelial Growth Factor (VEGF) which is an oral inhibitor of tyrosine kinase (TK) activity and acts through blockade of the TK receptor. Cediranib (AZD2171)" source :http://www.icon6.org/

No significant OS difference for cedirinib maintenance in ICON6. #ASCO17

— Robert Tyler Hillman (@RTylerHillmanMD) June 2, 2017

OC risk reduction w/ BRCA mutation:

#BRCA positive management and ovarian cancer #bcsm #ASCO17 pic.twitter.com/8CczkfZXLh

— Aleksandra Popadich (@alexpopadich) June 4, 2017

BRCA testing - ovarian cancer:

#BRCA testing should be performed on all women with ovarian cancer #bcsm #ASCO17 pic.twitter.com/TMHPFVdVci

— Aleksandra Popadich (@alexpopadich) June 4, 2017

Low rates of universal #brca testing in #ovariancancer 14- 40%. @EMBOSU poster 248 Mon 1:15 at #ASCO17 offers suggestions. Let's do better https://t.co/DhLdmofvP3

— Karen Lu (@karenluMD) June 5, 2017

Endometrial Cancer and Genetic Testing:

High-risk women with endometrial cancer lack receipt of genetic counseling referral https://t.co/y27fQiMvkk @IcahnMountSinai #ASCO17 #GynCSM pic.twitter.com/LhFBjItXSw

— HemOnc Today (@HemOncToday) June 5, 2017

Homologous Recombination Deficiency:

B. Norquist reviews and discusses HRD-related abstracts. (HRD=homologous recombination deficiency) #gyncsm#ASCO17 pic.twitter.com/Fa6f1xdTtu

— Erica Bednar (@EMBOSU) June 5, 2017

Germline Testing:

Important data as we increase tumor testing - the incidence of germline mutations that should be followed w #geneticcouns #ASCO17 #gyncsm https://t.co/Uar63lSn4f

— Shannon Westin (@ShannonWestin) June 5, 2017

Abstract 1524 http://abstracts.asco.org/199/AbstView_199_187114.html

Presented by Melinda Yates: proposed testing scheme for patients with ovarian cancer #gyncsm #ASCO17 pic.twitter.com/sRRcU6lAHJ

— Erica Bednar (@EMBOSU) June 5, 2017

from this study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048908/

Immunotherapy:

Informative presentation by @SamirNKhleif on state of combination immunotherapy in ovarian cancer. #ASCO17 #gyncsm pic.twitter.com/ODD9ah59tp

— Megan Hartranft (@MeganPharmD) June 4, 2017

Screening for OC:

Large studies UKCTOCS & PLCO not demonstrating benefit from ovarian cancer screening (studying survival, morbidity, mortality)#ASCO17

— Erica Bednar (@EMBOSU) June 4, 2017

Detection of Type II #ovariancancer rare in the PLCO through screening. But #overdiagnosis of less aggressive tumors common. #ASCO17 #gyncsm pic.twitter.com/0JwcpTy69R

— Sarah Temkin (@temkins) June 3, 2017

Fallopian Tube /Ovarian Cancer:

Shout out during talk to @karenluMD and Melinda Yates paper pic ( I'm also a fan of this diagram!)#ASCO17 pic.twitter.com/WAI5zDn2Xu

— Erica Bednar (@EMBOSU) June 4, 2017

Based on this study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048908/

Social Media:

Using social media to encourage physical activity in cancer patients #ASCO17 #gyncsm pic.twitter.com/6CLHnWLIkE

— Elizabeth Dickson (@edicksonMD) June 4, 2017

Join @Nikhilwagle @davidgrahammd and me in 5 minutes! #ASCO17 pic.twitter.com/ymBu4oEGbf

— Merry J Markham, MD (@DrMarkham) June 2, 2017

session description- https://iplanner.asco.org/am2017/#/session/12030
 
Li-Fraumeni Syndrome:

Whole body MRI picks up malignancies in a symptomatic Li-Fraumeni syndrome... #Asco17 pic.twitter.com/nq9LOTh55x

— Breelyn Wilky (@breelynwilky) June 5, 2017

Cost of Care:

Important work on cost of upfront treatment 4 #ovariancancer @SuidanRudyMD @LarissaAMeyerMD @karenluMD from @MDAndersonNews #ASCO17 #GynCSM https://t.co/ux4SvyuDaz

— Shannon Westin (@ShannonWestin) June 5, 2017

I hope I'll get the opportunity to report live from ASCO 2018.

Dee
Every Day is a Blessing!